This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:AB-CHMINACA: Difference between revisions
>Tracer m Changed Chemical class |
>LockPicker panels |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{decree|type=notice|message=This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.}} | |||
{{headerpanel|{{Approval}}}} | |||
{{SummarySheet}} | {{SummarySheet}} | ||
{{Talk:SubstanceBox/AB-CHMINACA}} | {{Talk:SubstanceBox/AB-CHMINACA}} | ||
| Line 12: | Line 14: | ||
==Pharmacology== | ==Pharmacology== | ||
{{pharmacology}} | |||
AB-CHMINACA is a selective CB1 receptor agonist, being approximately 30 times more active at CB1 over CB2. The reported EC<sub>50</sub> values are 7.4 ± 1.5nM at CB1 and 232.4 ± 231.2nM at CB2.<ref>Wiley JL, Marusich JA, Lefever TW, et al. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol–Like Effects in Mice. The Journal of Pharmacology and Experimental Therapeutics. 2015;354(3):328-339. doi:10.1124/jpet.115.225326. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538877/</ref> | AB-CHMINACA is a selective CB1 receptor agonist, being approximately 30 times more active at CB1 over CB2. The reported EC<sub>50</sub> values are 7.4 ± 1.5nM at CB1 and 232.4 ± 231.2nM at CB2.<ref>Wiley JL, Marusich JA, Lefever TW, et al. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol–Like Effects in Mice. The Journal of Pharmacology and Experimental Therapeutics. 2015;354(3):328-339. doi:10.1124/jpet.115.225326. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538877/</ref> | ||
| Line 21: | Line 24: | ||
*'''[[Effect::Sedation]]''' - Generally, the effects on the user's energy levels are primarily sedating. This encourages one to relax, and (at higher doses) fall asleep. This can be suppressed by simply forcing oneself to engage in physical activities. | *'''[[Effect::Sedation]]''' - Generally, the effects on the user's energy levels are primarily sedating. This encourages one to relax, and (at higher doses) fall asleep. This can be suppressed by simply forcing oneself to engage in physical activities. | ||
*'''[[Effect::Motor control loss]]''' - This substance causes a partial to moderate suppression of motor control which intensifies proportional to dose but rarely results in a complete inability to walk and perform basic movements. | *'''[[Effect::Motor control loss]]''' - This substance causes a partial to moderate suppression of motor control which intensifies proportional to dose but rarely results in a complete inability to walk and perform basic movements. | ||
*'''[[Effect::Appetite enhancement]]''' - As with many other cannabinoids, AB-CHMINACA causes an increase in appetite<ref>Mechoulam, R. (1984). Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press. ISBN 0-8493-5772-1.</ref>, known colloquially as "the munchies" in popular American and United Kingdom culture. Clinical studies and survey data have found that cannabis increases food enjoyment and interest in food.<ref>How Marijuana Works | http://science.howstuffworks.com/marijuana4.htm</ref> This is thought to be due to the way in which endocannabinoids in the hypothalamus activate cannabinoid receptors that are responsible for maintaining food intake.<ref> | *'''[[Effect::Appetite enhancement]]''' - As with many other cannabinoids, AB-CHMINACA causes an increase in appetite<ref>Mechoulam, R. (1984). Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press. ISBN 0-8493-5772-1.</ref>, known colloquially as "the munchies" in popular American and United Kingdom culture. Clinical studies and survey data have found that cannabis increases food enjoyment and interest in food.<ref name="HMW">How Marijuana Works | http://science.howstuffworks.com/marijuana4.htm</ref> This is thought to be due to the way in which endocannabinoids in the hypothalamus activate cannabinoid receptors that are responsible for maintaining food intake.<ref name="HMW"></ref> | ||
*'''[[Effect::Changes in gravity]]''' - AB-CHMINACA can cause vertigo with which the environment appears to be spinning or oscillating. At moderate doses, it can spontaneously induce the sensation of falling, which can be overwhelming and uncomfortable. | *'''[[Effect::Changes in gravity]]''' - AB-CHMINACA can cause vertigo with which the environment appears to be spinning or oscillating. At moderate doses, it can spontaneously induce the sensation of falling, which can be overwhelming and uncomfortable. | ||
*'''[[Effect::Perception of bodily heaviness]]''' ''or'' '''[[Perception of bodily lightness]]''' | *'''[[Effect::Perception of bodily heaviness]]''' ''or'' '''[[Perception of bodily lightness]]''' | ||
| Line 46: | Line 49: | ||
*'''[[Effect::Dream suppression]]''' | *'''[[Effect::Dream suppression]]''' | ||
*'''[[Effect::Immersion enhancement]]''' | *'''[[Effect::Immersion enhancement]]''' | ||
*'''[[Effect::Psychosis]]''' - The prolonged usage of synthetic [[cannabinoids]] may increase one's disposition to psychosis<ref>Causal association between cannabis and psychosis: examination of the evidence - The British Journal of Psychiatry Jan 2004, 184 (2) 110-117 | http://bjp.rcpsych.org/content/184/2/110.short</ref>, particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).<ref>Every-Palmer, S. [[Synthetic cannabinoid]] use and psychosis: an explorative study. Journal of Drug and Alcohol Dependence 2011.</ref><ref>“Spice” Girls: Synthetic Cannabinoid Intoxication - The Journal of Emergency Medicine Volume 40, Issue 3, March 2011, Pages 296–299 (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0736467910008802</ref><ref>A Teenager With Agitation: Higher Than She Should Have Climbed - Pediatric Emergency Care: June 2010 - Volume 26 - Issue 6 - pp 462-465 | http://journals.lww.com/pec-online/Abstract/2010/06000/A_Teenager_With_Agitation__Higher_Than_She_Should.16.aspx</ref> | *'''[[Effect::Psychosis]]''' - The prolonged usage of synthetic [[cannabinoids]] may increase one's disposition to psychosis<ref name="Arseneault2004">Causal association between cannabis and psychosis: examination of the evidence - The British Journal of Psychiatry Jan 2004, 184 (2) 110-117 | http://bjp.rcpsych.org/content/184/2/110.short</ref>, particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).<ref name="Every-Palmer2011">Every-Palmer, S. [[Synthetic cannabinoid]] use and psychosis: an explorative study. Journal of Drug and Alcohol Dependence 2011.</ref><ref name="Schneir2011">“Spice” Girls: Synthetic Cannabinoid Intoxication - The Journal of Emergency Medicine Volume 40, Issue 3, March 2011, Pages 296–299 (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0736467910008802</ref><ref name="Vearrier2010">A Teenager With Agitation: Higher Than She Should Have Climbed - Pediatric Emergency Care: June 2010 - Volume 26 - Issue 6 - pp 462-465 | http://journals.lww.com/pec-online/Abstract/2010/06000/A_Teenager_With_Agitation__Higher_Than_She_Should.16.aspx</ref> | ||
*'''[[Effect::Personal meaning enhancement]]''' | *'''[[Effect::Personal meaning enhancement]]''' | ||
*'''[[Effect::Increased music appreciation]]''' | *'''[[Effect::Increased music appreciation]]''' | ||
| Line 56: | Line 59: | ||
}} | }} | ||
}} | }} | ||
===Experience reports=== | ===Experience reports=== | ||
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here: | There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here: | ||
| Line 66: | Line 70: | ||
It is worth noting that this compound has been linked to multiple hospitalizations and deaths due to its use.<ref>Synthetic Cannabinoid–Related Illnesses and Deaths | http://www.nejm.org/doi/full/10.1056/NEJMp1505328</ref><ref>Suicide attempt with a mix of [[synthetic cannabinoids]] and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC | http://www.fsijournal.org/article/S0379-0738(16)00037-2/abstract</ref> | It is worth noting that this compound has been linked to multiple hospitalizations and deaths due to its use.<ref>Synthetic Cannabinoid–Related Illnesses and Deaths | http://www.nejm.org/doi/full/10.1056/NEJMp1505328</ref><ref>Suicide attempt with a mix of [[synthetic cannabinoids]] and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC | http://www.fsijournal.org/article/S0379-0738(16)00037-2/abstract</ref> | ||
It has often been recommended that those with severe pre-existing mental conditions should not ingest these substances due to the way they strongly increase [[emotion enhancement|one's current state of mind and emotions]]. Also, like [[THC]], prolonged usage of synthetic [[cannabinoids]] may increase one's disposition to mental illness and psychosis<ref> | It has often been recommended that those with severe pre-existing mental conditions should not ingest these substances due to the way they strongly increase [[emotion enhancement|one's current state of mind and emotions]]. Also, like [[THC]], prolonged usage of synthetic [[cannabinoids]] may increase one's disposition to mental illness and psychosis<ref name="Arseneault2004"></ref>, particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).<ref name="Every-Palmer2011"></ref><ref name="Schneir2011"></ref><ref name="Vearrier2010"></ref> | ||
As synthetic cannabinoids are active in the milligram range (with below 1mg being a typical dose for AB-CHMINACA), it is important to [[Dosage|use proper precautions when dosing]] to avoid a negative experience. | As synthetic cannabinoids are active in the milligram range (with below 1mg being a typical dose for AB-CHMINACA), it is important to [[Dosage|use proper precautions when dosing]] to avoid a negative experience. | ||
| Line 78: | Line 82: | ||
==Legal status== | ==Legal status== | ||
*'''Brazil | *'''Brazil''': On August 21, 2018, AB-CHMINACA was added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.<ref>List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial</ref> | ||
*'''China | *'''China''': As of October 2015, AB-CHMINACA is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref> | ||
*'''Germany:''' | *'''Germany:''' AB-CHMINACA is controlled under Anlage II BtMG (''Narcotics Act, Schedule II'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html|title=Anlage II BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 30, 2019|language=de}}</ref> as of May 23, 2015.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl115s0723.pdf|title=Neunundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2015 Teil I Nr. 19|pages=723-724|publication-date=May 22, 2015|access-date=December 19, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 19, 2019|language=de}}</ref> | ||
*'''United Kingdom | *'''Switzerland''': AB-CHMINACA is a controlled substance.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Der Bundesrat|access-date=December 29, 2019|language=de}}</ref> | ||
*'''United States | *'''United Kingdom''': AB-CHMINACA is a Class B controlled substance under the third-generation synthetic cannabinoids generic definition, which came into effect on December 14, 2016. It is illegal to possess, produce, supply, or import. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2016/1109/made</ref> | ||
*'''United States''': In January 2015, AB-CHMINACA was designated as a Schedule I controlled substance in the United States.<ref>Federal Register Vol. 80 No. 20, Friday January 30, 2015. "Schedules of Controlled Substances: Temporary Placement of Three Synthetic Cannabinoids Into Schedule I" (GPO.gov) | https://www.gpo.gov/fdsys/pkg/FR-2015-01-30/pdf/2015-01776.pdf</ref> | |||
==See also== | ==See also== | ||
| Line 91: | Line 95: | ||
*[[AB-FUBINACA]] | *[[AB-FUBINACA]] | ||
*[[THJ-018]] | *[[THJ-018]] | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/AB-CHMINACA AB-CHMINACA (Wikipedia)] | *[https://en.wikipedia.org/wiki/AB-CHMINACA AB-CHMINACA (Wikipedia)] | ||
| Line 97: | Line 102: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Articles in talk page]] | ||
[[Category: | [[Category:Research chemical]] | ||
[[Category: | [[Category:Indazolecarboxamide]] | ||
[[Category:Cannabinoid]] | [[Category:Cannabinoid]] | ||